Rathbones Group PLC Has $9.32 Million Position in DexCom, Inc. $DXCM

Rathbones Group PLC cut its holdings in DexCom, Inc. (NASDAQ:DXCM) by 79.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 138,523 shares of the medical device company’s stock after selling 551,828 shares during the quarter. Rathbones Group PLC’s holdings in DexCom were worth $9,321,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. raised its position in shares of DexCom by 2.3% during the 3rd quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company’s stock valued at $3,327,897,000 after acquiring an additional 1,133,638 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of DexCom by 3.4% in the 2nd quarter. Geode Capital Management LLC now owns 10,766,356 shares of the medical device company’s stock worth $936,100,000 after purchasing an additional 358,617 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of DexCom by 106.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 6,605,687 shares of the medical device company’s stock worth $576,610,000 after purchasing an additional 3,410,858 shares during the period. Norges Bank acquired a new stake in shares of DexCom during the second quarter worth $453,279,000. Finally, Groupama Asset Managment increased its holdings in DexCom by 79,043.1% in the second quarter. Groupama Asset Managment now owns 4,016,513 shares of the medical device company’s stock valued at $350,601,000 after purchasing an additional 4,011,438 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Trading Down 3.7%

NASDAQ:DXCM opened at $68.10 on Monday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.88 and a quick ratio of 1.59. The business’s 50-day simple moving average is $70.69 and its 200-day simple moving average is $68.75. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $89.98. The stock has a market capitalization of $26.21 billion, a PE ratio of 32.43, a price-to-earnings-growth ratio of 1.32 and a beta of 1.48.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.03. The business had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.25 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.DexCom’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.45 EPS. Sell-side analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

DXCM has been the topic of several analyst reports. Sanford C. Bernstein reissued an “outperform” rating and issued a $86.00 target price (up from $84.00) on shares of DexCom in a research note on Friday, January 9th. Truist Financial reaffirmed a “buy” rating and issued a $80.00 price target (down from $82.00) on shares of DexCom in a research note on Tuesday, February 17th. Morgan Stanley reiterated an “overweight” rating on shares of DexCom in a research report on Monday, January 12th. Citigroup reissued a “buy” rating and set a $77.00 price objective (up from $75.00) on shares of DexCom in a research note on Thursday, December 11th. Finally, Weiss Ratings upgraded shares of DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $85.18.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.